Bristol Myers Squibb (CELG-RI) Cash & Current Investments (2009 - 2026)

Bristol Myers Squibb has disclosed Cash & Current Investments across 18 years of filings, most recently posting $10.5 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 11.0% year-over-year to $10.5 billion; the TTM figure through Mar 2026 stood at $10.5 billion (down 11.0% YoY), while the FY2025 annual figure was $10.7 billion, down 1.71% from the prior year.
• Cash & Current Investments eased to $10.5 billion in Q1 2026, from $10.7 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for CELG-RI reached as high as $16.5 billion in Q3 2025 and fell as low as $6.7 billion in Q2 2024.
• The 5-year median for Cash & Current Investments is $10.5 billion (2026), against an average of $10.8 billion.
• Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 45.46% — and 2025, when it surged 104.46%.
• A 5-year view of Cash & Current Investments shows it stood at $9.3 billion in 2022, then surged by 32.71% to $12.3 billion in 2023, then slipped by 11.57% to $10.9 billion in 2024, then declined by 1.71% to $10.7 billion in 2025, then declined by 1.75% to $10.5 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $10.5 billion, $10.7 billion, and $16.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.